Amend 003 - Hepatitis A Adult and Pediatric - GlaxoSmithKline Inc.
Contract number E60PH-22HEPA/002/PH
Solicitation number E60PH-22HEPA/A
Contract award date
Expiry date
Amendment date
Amendment value CAD 1,311,091.54
Contract number E60PH-22HEPA/002/PH
Solicitation number E60PH-22HEPA/A
Contract award date
Expiry date
Amendment date
Amendment value CAD 1,311,091.54
This contract was awarded to:
The contract will be for a period of 36 month(s), from 2022/03/04 to 2025/03/31.
This is the total value of this contract, which includes the initial contract value and the sum of all amendments.
CAD 3,152,686.13